Mannatech deal
This article was originally published in The Tan Sheet
Executive Summary
Coppell, Tex.-based firm enters into exclusive multi-year supply agreement with Marinova, an Australian biotech firm specializing in biotherapeutics derived from the macro algae Undaria pinnatifida (brown seaweed), Mannatech announces. The contract is "part of an ongoing effort to secure the best and most exclusive worldwide sources of natural, plant-synthesized polysaccharide structures," CEO Sam Caster says. Marinova has developed a method of using a sulphate polysaccharide galactofucan sulphate and created "a patent-pending high-molecular weight fucoidan product," according to a release...
You may also be interested in...
Mannatech earnings
Coppell, Texas-based supplement firm's sales increased 56.1% to $77.6 mil. with earnings up 136% to $6.8 mil. in the third quarter, Mannatech announces Nov. 9. The results mark the firm's eighth consecutive quarter of growth, and include its September entry into the South Korean market and signing of a deal with Australian biotech firm Marinova to make microalgae-derived biotherapeutics (1"The Tan Sheet" Sept. 13, 2004, In Brief)...
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.